RSS Amplifier

Heart Matters · Aug 10, 2026

Evaluating ASCVD Risk with the CPR Framework

0
Sign in to vote or save

Home - www.ushealthconnect.com · reachmd.com

ReachMD

Be part of the knowledge.

ReachMD Healthcare Image

Restart Restart Program

Resume Play Program

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

  • Overview

    The 2026 American College of Cardiology (ACC) and American Heart Association (AHA) Guideline on the Management of Dyslipidemia highlights the CPR framework—Calculate, Personalize, Reclassify, and Reassess—to support individualized atherosclerotic cardiovascular disease (ASCVD) risk assessment and treatment decisions. Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, joins us to explain how clinicians can combine PREVENT risk estimates with risk-enhancing factors, coronary artery calcium scoring, and shared decision-making to improve cardiovascular prevention strategies. Dr. Blumenthal is also the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.

  • Overview

    The 2026 American College of Cardiology (ACC) and American Heart Association (AHA) Guideline on the Management of Dyslipidemia highlights the CPR framework—Calculate, Personalize, Reclassify, and Reassess—to support individualized atherosclerotic cardiovascular disease (ASCVD) risk assessment and treatment decisions. Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, joins us to explain how clinicians can combine PREVENT risk estimates with risk-enhancing factors, coronary artery calcium scoring, and shared decision-making to improve cardiovascular prevention strategies. Dr. Blumenthal is also the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.

Read the original on reachmd.com

Comments

Nothing yet. Say the first thing.

    Sign in to join the conversation.